Navigation Links
Computer modeling reveals how surprisingly potent hepatitis C drug works
Date:2/20/2013

LOS ALAMOS, N.M., Feb. 19, 2013A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs within 12 hours of treatment.

Chronic infection with hepatitis C virus affects about 150 million people worldwide. It is the leading cause of cirrhosis, liver cancer and liver transplants and results in some 350,000 deaths worldwide every year.

The team's work reveals that daclatasvir has two primary modes of action against HCV and also provides a more accurate estimate of the HCV half-life. Until 2011, treatment options were limited and offered modest effectiveness; fewer than half of treated patients were fully cured of the virus. In the last decade, active research on understanding the mechanisms of HCV replication resulted in the discovery of direct acting antivirals targeting all stages of the viral replication process.

The new mathematical analysis of the rapid viral decline observed after one dose of daclatasvir reveals that the drug blocks two stages of the viral lifecycle and that the HCV half-life in serum is four times shorter than previously thought according to a study published in Proceedings of the National Academy of Sciences USA.

The NS5A protein within the hepatitis virus is a specific target for drug development. The first NS5A inhibitor, daclatasvir, developed by Bristol Myers Squibb, showed one of the most potent effects in combating HCV; one dose led to a thousand-fold decrease in viral levels within about 12 hours. Oddly, however NS5A has no known enzymatic functions making it difficult to understand its mode of action and design optimal drug combinations.

"Unraveling how this drug could cause such a rapid drop in the amount of virus in an infected person's blood c
'/>"/>

Contact: Nancy Ambrosiano
nwa@lanl.gov
505-699-1149
DOE/Los Alamos National Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. New supercomputer to aid genomics research
2. New supercomputer coming to EMSL this summer, supplied by Atipa Technologies
3. Virginia Tech computer scientists develop new way to study molecular networks
4. Iowa State computer, electrical engineers working to help biologists cope with big data
5. How computers push on the molecules they simulate
6. Total donates high-speed computer cluster to UH
7. A better thought-controlled computer cursor
8. Computers taught to ID regulating gene sequences
9. Computer simulations for multiscale systems can be faster, better, more reliable
10. Computer viruses could take a lesson from showy peacocks
11. NPointer from Neurotechnology Uses Hand Gestures to Control and Navigate Computer Programs Without a Mouse or Touchpad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... for providing essential fatty acids and energy to ... has been concern that soybean-based emulsions could compromise ... its composition. Combination lipid emulsions based on triglyceride ... developed to address this concern. , However, researchers ... may be unwarranted, according to a review published ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2014. Revenue for the ... 53% compared to $4.4 million in the same quarter last ... quarter of 2014 was $1.4 million compared to $0.5 million ... and operating income was driven by higher sales of software ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... , June 19, 2013  Paris Air Show – ... Systems) , a leading provider of innovative test solutions ... solutions this week at the Paris Air Show ... complex armament systems with longer lifecycles, industry leaders are ...
... University, sophisticated computational models and advances in graphical processing ... genomic data, virus structure and the formation of the ... "We hope that some of what we are ... unable to replicate," says post-doctoral fellow Jason Perlmutter, first ...
... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ...
Cached Biology News:Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Computer modeling technique goes viral at Brandeis 2The American Society for Microbiology honors Joshua Obar 2
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 /PRNewswire/ - ... industrial biotechnology company producing sustainable chemicals, today announced that ... in full their option to purchase an additional ... offering price of $12.00 per share, less underwriting ... announced underwritten public offering of 2,800,000 shares of ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... , July 23, 2014 ... ), the global specialty biopharmaceutical company, and ArmaGen, ... a worldwide licensing and collaboration agreement for AGT-182, ... potential treatment of both the central nervous system ... syndrome (MPS II). This collaboration strengthens Shire,s rare ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Bunge North America, the North American operating arm of Bunge ... which can be attributed to Soren Schroder, Bunge North America ... aware from press reports of Syngenta,s allegations.  From what we ... and disappointed that Syngenta has taken an action which could ...
... 23, 2011 MedNet Solutions, a global life sciences technology ... to announce that MedNet has once again been recognized by ... held companies in the United States.  MedNet is greatly honored ... straight year, since, as noted by Inc . magazine, ...
... FMC Corporation (NYSE: FMC ) announced today ... agreements covering global development and supply of Chr. Hansen ... begin commercialization this year of Chr. Hansen,s Nemix bacillus ... standalone and combination products in the Americas and key ...
Cached Biology Technology:Bunge Responds to Syngenta Suit 2MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row 2FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
... 500 reactions. Prepare circular DNA templates ... microgram quantities of template DNA from ... DNA directly for cycle sequencing without ... liquid cultures, colonies, plaques, or purified ...
...
Biology Products: